Comparing two therapies for advanced liver cancer after first treatment fails
Part of Cancer clinical trials.
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) that cannot be surgically removed.
- Your cancer has continued to grow after at least 2 cycles of a first treatment with bevacizumab and sintilimab.
- You then received at least 2 cycles of a second treatment, either continuing bevacizumab/sintilimab or switching to lenvatinib or regorafenib with a PD-1 inhibitor.
- Your liver function is fairly good (Child-Pugh class A or B) and you are generally well enough to be up and about (ECOG score 0-2).
- Your blood counts and liver/kidney function are within certain safe limits (e.g., hemoglobin ≥8.5, platelets ≥75,000, bilirubin ≤30).
- You are 18 to 75 years old and can give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Hear when a new Hepatocellulcar Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.